MV MANAGEMENT XI L L C
Q4 2021 Form 13-F
MENLO PARK, CALIFORNIA
CIK 0001503556
· CRD 161248
· Exempt reporting adviser
$231.5M Reported Value Total
Exempt Reporting Adviser
menlovc.com
Source: Form ADV filed 2026-04-01
Reported value
$231.5M
Quarter over quarter
0.0%
Holdings
4
Top-10 concentration
100.0%
Key People
Named on the latest Form 13-F filing — not necessarily an owner
Venky Ganesan
Managing Member of General Partner
Filing Navigation
13F Metrics
Loading 13F Metrics
Q4 2021 13F record
Q4 2021 13F filing summary
| Period of report | December 31, 2021 |
|---|---|
| Filed | February 15, 2022 |
| Form | 13F-HR |
| Reported value | $231.5M |
| Positions | 4 |
| Change in reported value | First reported quarter |
| Top-10 concentration | 100.0% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q3 2023 13F
Filed Nov 14, 2023
|
3 | $60.1M |
|
Q2 2023 13F
Filed Jul 24, 2023
|
3 | $57.2M |
|
Q1 2023 13F
Filed May 2, 2023
|
3 | $65.3M |
|
Q4 2022 13F
Filed Jan 31, 2023
|
3 | $57.5M |
|
Q3 2022 13F
Filed Nov 14, 2022
|
4 | $138.0M |
|
Q2 2022 13F
Filed Jul 28, 2022
|
4 | $110.0M |
|
Q1 2022 13F
Filed May 16, 2022
|
4 | $144.0M |
|
Q4 2021 13F
Filed Feb 15, 2022
|
4 | $231.5M |
Top 4 holdings · Q4 2021
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | ROVR ROVER GROUP INC | $112.3M | 48.52% |
| 2 | POSH POSHMARK INC | $85.4M | 36.88% |
| 3 | RXRX RECURSION PHARMACEUTICALS IN | $33.8M | 14.59% |
| 4 | ANGI ANGI INC | $17.0K | < 0.01% |
Values as reported on the Q4 2021 Form 13F. Every position is in the holdings table below.